North American Osteoarthritis Therapeutics Market
North America Osteoarthritis Therapeutics Market Size, Share and Trends Analysis Report by Anatomy (Knee Osteoarthritis, Ankle and Foot Osteoarthritis, Hip Osteoarthritis, Shoulder Osteoarthritis, Spine Osteoarthritis, and Others), by Drug Type (NSAIDs, Corticosteroids, Analgesics, Opioid Analgesics, Biologics, Viscosupplementation Agents, Regenerative Medicine and Therapies, and Others), Forecast Period, 2026–2035
Industry Overview
North America osteoarthritis therapeutics market was valued at $4,256.0 million in 2025 and is projected to reach $9,551.3 million by 2035, growing at a CAGR of 8.2% during the forecast period (2026–2035). The North American osteoarthritis therapeutics market is expanding at a steady pace, supported by a high prevalence of knee, hip, and spine osteoarthritis linked to aging populations, obesity trends, and active lifestyles. Knee osteoarthritis remains the largest treated segment due to its impact on mobility and quality of life, while hip and spine indications continue to see rising intervention rates driven by improved diagnosis and earlier treatment initiation.
From a drug perspective, NSAIDs and analgesics maintain broad usage for symptom management, especially in early-stage disease, supported by strong physician familiarity and reimbursement coverage. Corticosteroid and viscosupplementation injections remain widely adopted for moderate disease, particularly in outpatient and orthopedic settings. Biologics and regenerative therapies, including platelet-rich plasma and cell-based approaches, are gaining attention as clinicians seek longer-lasting outcomes and alternatives to surgery. Ongoing clinical research, favorable regulatory pathways for novel therapies, and strong pharmaceutical presence across the US and Canada continue to reinforce long-term market growth.
Market Dynamics
Rising Disease Burden and Demand for Long-Term Pain Management
Osteoarthritis prevalence across North America continues to rise, driven by aging demographics, increasing obesity rates, and higher participation in physically demanding activities. Knee and hip osteoarthritis account for a substantial share of diagnosed cases due to their direct impact on mobility and daily functioning. This growing patient pool is sustaining consistent demand for pharmacological therapies aimed at pain relief, inflammation control, and functional improvement. Early diagnosis and proactive treatment approaches are also expanding the treated population, reinforcing prescription volumes across primary care, rheumatology, and orthopedic settings.
Shift Toward Advanced and Minimally Invasive Therapeutic Options
NSAIDs, analgesics, and corticosteroids continue to serve as first-line therapies in osteoarthritis management; however, concerns around long-term safety and inconsistent clinical outcomes are driving interest in alternative treatment options. Viscosupplementation agents maintain steady adoption, especially in knee osteoarthritis, as clinicians seek to postpone or avoid surgical intervention. In parallel, biologics and regenerative medicine therapies are gaining traction, supported by expanding clinical evidence, higher patient acceptance of non-surgical approaches, and the growth of private specialty clinics.
Market Segmentation
- Based on anatomy, the market is segmented into knee osteoarthritis, ankle and foot osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, spine osteoarthritis, and others.
- Based on drug type, the market is segmented into NSAIDs, corticosteroids, analgesics, opioid analgesics, biologics, viscosupplementation agents, regenerative medicine and therapies, and others.
Knee Osteoarthritis Driving Treatment Demand
Knee osteoarthritis has emerged as the largest treated anatomy segment in North America, driven by its high prevalence among aging populations, overweight individuals, and physically active adults. The condition significantly affects mobility and daily functioning, leading to early clinical intervention and repeated treatment cycles. Strong demand exists for NSAIDs, analgesics, corticosteroid injections, and viscosupplementation therapies, particularly in outpatient orthopedic and pain management settings. Advances in imaging, earlier diagnosis, and patient preference to delay joint replacement surgery are further sustaining treatment volumes. As a result, knee-focused therapies continue to account for a substantial share of overall market revenues.
Biologics and Regenerative Therapies Gaining Momentum
Regenerative medicine and biologic therapies represent one of the fastest-growing segments in the North American osteoarthritis therapeutics market. Increasing interest in platelet-rich plasma, cell-based therapies, and disease-modifying approaches reflects the need for longer-lasting symptom relief beyond conventional pharmacological options. Adoption is being supported by growing clinical evidence, expanding private orthopedic and sports medicine clinics, and patient willingness to pursue non-surgical interventions. Pharmaceutical and biotech companies are actively advancing clinical pipelines and real-world studies to strengthen efficacy and safety profiles. This shift toward advanced therapies is accelerating innovation and is expected to remain a key growth driver over the forecast period.
Regional Outlook
North America osteoarthritis therapeutics market is further divided by countries, including US and Canada.
US Dominates the Market with Major Share
The US osteoarthritis therapeutics market is seeing significant demand owing to a growing elderly population, high obesity prevalence, and widespread incidence of joint-related disorders. Early diagnosis, strong access to specialist care, and high treatment awareness support consistent therapy adoption across knee, hip, and spine osteoarthritis. The presence of leading pharmaceutical and biotechnology companies, along with active clinical trial activity, is accelerating the introduction of advanced therapies. Well-established reimbursement systems and higher healthcare spending further strengthen treatment uptake. Together, these factors position the US as the dominant contributor to overall market revenues in North America.
Market Players Outlook
The major companies operating in the North America Osteoarthritis Therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Eli Lilly and Company, Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., Pacira BioSciences, Inc., Zimmer Biomet Holdings, Inc., Anika Therapeutics, Inc., and Bioventus Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions, along with continuous product innovation, to strengthen their competitive positioning and expanding their presence across key treatment segments.
Recent Developments
- In September 2025, Pfizer reported positive top-line results from its Phase 3 trial of PF-06730512, a novel monoclonal antibody targeting cartilage degradation pathways in knee osteoarthritis. The trial met its primary endpoint for pain reduction and showed improved joint function scores compared with placebo, positioning the candidate for submission to the U.S. Food and Drug Administration in early 2026.
- In July 2025, Johnson & Johnson MedTech announced a strategic co-promotion agreement with Pacira BioSciences to expand early intervention options for knee osteoarthritis, leveraging the extended-release injectable Zilretta and shared professional education initiatives to enhance access to non-surgical pain treatment.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the North America osteoarthritis therapeutics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- North American Osteoarthritis Therapeutics Market Sales Analysis – Anatomy | Drug Type ($ Million)
- North American Osteoarthritis Therapeutics Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key North America Osteoarthritis Therapeutics Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Osteoarthritis Therapeutics Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For North American Osteoarthritis Therapeutics Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For North American Osteoarthritis Therapeutics Market: Impact Analysis
- Market Opportunities
- Opportunities For North American Osteoarthritis Therapeutics Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – North America Osteoarthritis Therapeutics Market Revenue and Share by Manufacturers
- North America Osteoarthritis Therapeutics Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson & Johnson
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- AbbVie Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Eli Lilly and Co.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck & Co., Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Pfizer Inc.
- Key Company Analysis
- North American Osteoarthritis Therapeutics Market Sales Analysis by Anatomy ($ Million)
- Knee Osteoarthritis
- Ankle and Foot Osteoarthritis
- Hip Osteoarthritis
- Shoulder Osteoarthritis
- Spine Osteoarthritis
- Others
- North American Osteoarthritis Therapeutics Market Sales Analysis by Drug Type ($ Million)
- NSAIDs
- Corticosteroids
- Analgesics
- Opioid Analgesics
- Biologics
- Viscosupplementation Agents
- Regenerative Medicine/ Therapies
- Others
- Regional Analysis
- North American Osteoarthritis Therapeutics Market Sales Analysis – Anatomy | Drug Type | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- Company Profiles
- Anika Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Anika Therapeutics, Inc.
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Boehringer Ingelheim GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Chiesi Farmaceutici S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Egis Pharmaceuticals Plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ferring Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Fidia Farmaceutici S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GSK plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Grünenthal GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- IBSA SA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipsen S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- KRKA d.d.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Menarini Group S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Orion Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Perrigo Co. Plc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reckitt Plc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Recordati S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sandoz AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Smith & Nephew Plc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- STADA Arzneimittel AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
1. North American Osteoarthritis Therapeutics Market Research and Analysis by Anatomy, 2025–2035 ($ Million)
2. North American Knee Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
3. North American Ankle and Foot Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
4. North American Hip Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
5. North American Shoulder Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
6. North American Spine Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
7. North American Other Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
8. North American Osteoarthritis Therapeutics Market Research and Analysis by Drug Type, 2025–2035 ($ Million)
9. North American NSAIDs for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
10. North American Corticosteroids for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
11. North American Analgesics for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
12. North American Opioid Analgesics for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
13. North American Biologics for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
14. North American Viscosupplementation Agents for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
15. North American Regenerative Medicine and Therapies for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
16. North American Other Drugs for Osteoarthritis Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
17. North American Osteoarthritis Therapeutics Market Research and Analysis by Country, 2025–2035 ($ Million)
18. North American Osteoarthritis Therapeutics Market Research and Analysis by Anatomy, 2025–2035 ($ Million)
19. North American Osteoarthritis Therapeutics Market Research and Analysis by Drug Type, 2025–2035 ($ Million)
1. North American Osteoarthritis Therapeutics Market Share by Anatomy, 2025 Vs 2035 (%)
2. North American Knee Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
3. North American Ankle and Foot Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
4. North American Hip Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
5. North American Shoulder Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
6. North American Spine Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
7. North American Other Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
8. North American Osteoarthritis Therapeutics Market Share by Drug Type, 2025 Vs 2035 (%)
9. North American NSAIDs for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
10. North American Corticosteroids for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
11. North American Analgesics for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
12. North American Opioid Analgesics for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
13. North American Biologics for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
14. North American Viscosupplementation Agents for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
15. North American Regenerative Medicine and Therapies for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
16. North American Others for Osteoarthritis Therapeutics Market Share by Region, 2025 Vs 2035 (%)
17. North American Osteoarthritis Therapeutics Market Share by Region, 2025 vs 2035 (%)
18. US Osteoarthritis Therapeutics Market Size, 2025–2035 ($ Million)
19. Canada Osteoarthritis Therapeutics Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
